Roland Fiskesund

Om mig
Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Om mig

Team leader och forskningsspecialist med fokus på Transfusionsmedicin och
Stamcellsbiologi
Medicine Doktor och ST-läkare i Klinisk Immunologi och Transfusionsmedicin.

Forskningsbeskrivning

Transfusionsmedicin är en av hörnstenarna i modern medicin och
forskningfältet har stor translationell potential.
Transfusion av blodplättar och röda blodkroppar används dagligen på våra
svenska sjukhus. Vårt huvudsakliga forskningsintresse är att utforska
konceptet neutrofiltransfusion till neutropena patienter som saknar
egenproduktion av dessa vita blodkroppar.
Andra forskningsprojekt som vi arbetar med inkluderar enzymatisk konvertering
av blodgrupper, citratmetabolism vid aferes och processning av
stamcellsprodukter.

Artiklar

Article: NATURE COMMUNICATIONS. 2024;15(1):1405
Cell softness renders cytotoxic T lymphocytes and T leukemic cells resistant to perforin-mediated killing
Zhou Y; Wang D; Zhou L; Zhou N; Wang Z; Chen J; Pang R; Fu H; Huang Q; Dong F; Cheng H; Zhang H; Tang K; Ma J; Lv J; Cheng T; Fiskesund R; Zhang X; Huang B
Article: NATURE IMMUNOLOGY. 2023;24(12):2042-2052
Tumor cell-released kynurenine biases MEP differentiation into megakaryocytes in individuals with cancer by activating AhR-RUNX1
Zhou L; Wu D; Zhou Y; Wang D; Fu H; Huang Q; Qin G; Chen J; Lv J; Lai S; Zhang H; Tang K; Ma J; Fiskesund R; Zhang Y; Zhang X; Huang B
Article: CELL DEATH AND DIFFERENTIATION. 2022;29(1):246-261
MTH1 as a target to alleviate T cell driven diseases by selective suppression of activated T cells.
Karsten S; Fiskesund R; Zhang X-M; Marttila P; Sanjiv K; Pham T; Rasti A; Bräutigam L; Almlöf I; Marcusson-Ståhl M; Sandman C; Platzack B; Harris RA; Kalderén C; Cederbrant K; Helleday T; Warpman Berglund U
Article: CANCER RESEARCH. 2021;81(2):476-488
Cell Softness Prevents Cytolytic T-cell Killing of Tumor-Repopulating Cells
Liu Y; Zhang T; Zhang H; Li J; Zhou N; Fiskesund R; Chen J; Lv J; Ma J; Zhang H; Tang K; Cheng F; Zhou Y; Zhang X; Wang N; Huang B
Article: ACR OPEN RHEUMATOLOGY. 2020;2(6):344-356
Immunoglobulin G1 Antibodies Against Phosphorylcholine Are Associated With Protection in Systemic Lupus Erythematosus and Atherosclerosis: Potential Underlying Mechanisms
Thiagarajan D; Fiskesund R; Frostegard A; Steen J; Rahman M; Vikstroem M; Lundstroem S; Frostegard J
Article: CANCER IMMUNOLOGY RESEARCH. 2018;6(9):1057-1068
Mechanisms by Which Dendritic Cells Present Tumor Microparticle Antigens to CD8+ T Cells.
Ma J; Wei K; Zhang H; Tang K; Li F; Zhang T; Liu J; Xu P; Yu Y; Sun W; Zhu L; Chen J; Zhou L; Liang X; Lv J; Fiskesund R; Liu Y; Huang B
Article: CANCER RESEARCH. 2018;78(14):3926-3937
Fibrin Stiffness Mediates Dormancy of Tumor-Repopulating Cells via a Cdc42-Driven Tet2 Epigenetic Program.
Liu Y; Lv J; Liang X; Yin X; Zhang L; Chen D; Jin X; Fiskesund R; Tang K; Ma J; Zhang H; Dong W; Mo S; Zhang T; Cheng F; Zhou Y; Xie J; Wang N; Huang B
Article: CANCER CELL. 2018;33(3):480-494.e7
Tumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR Activation.
Liu Y; Liang X; Dong W; Fang Y; Lv J; Zhang T; Fiskesund R; Xie J; Liu J; Yin X; Jin X; Chen D; Tang K; Ma J; Zhang H; Yu J; Yan J; Liang H; Mo S; Cheng F; Zhou Y; Zhang H; Wang J; Li J; Chen Y; Cui B; Hu Z-W; Cao X; Xiao-Feng Qin F; Huang B
Article: JOURNAL OF CLINICAL INVESTIGATION. 2018;128(3):1057-1073
STAT3/p53 pathway activation disrupts IFN-β-induced dormancy in tumor-repopulating cells
Liu Y; Lv J; Liu J; Liang X; Jin X; Xie J; Zhang L; Chen D; Fiskesund R; Tang K; Ma J; Zhang H; Dong W; Mo S; Zhang T; Cheng F; Zhou Y; Jia Q; Zhu B; Kong Y; Guo J; Zhang H; Hu Z-W; Cao X; Qin FX-F; Huang B
Article: NATURE COMMUNICATIONS. 2018;9(1):873
Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype.
Chen D; Xie J; Fiskesund R; Dong W; Liang X; Lv J; Jin X; Liu J; Mo S; Zhang T; Cheng F; Zhou Y; Zhang H; Tang K; Ma J; Liu Y; Huang B
Article: CLINICAL IMMUNOLOGY. 2016;166:27-37
IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms
Rahman M; Sing S; Golabkesh Z; Fiskesund R; Gustafsson T; Jogestrand T; Frostegard AG; Hafstrom I; Liu A; Frostegard J
Article: ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY. 2015;35(1):197-205
Induction of Dendritic Cell-Mediated T-Cell Activation by Modified but Not Native Low-Density Lipoprotein in Humans and Inhibition by Annexin A5 Involvement of Heat Shock Proteins
Liu A; Ming JY; Fiskesund R; Ninio E; Karabina S-A; Bergmark C; Frostegard AG; Frostegard J
Article: JOURNAL OF IMMUNOLOGY. 2014;192(10):4551-4559
Naturally Occurring Human Phosphorylcholine Antibodies Are Predominantly Products of Affinity-Matured B Cells in the Adult
Fiskesund R; Steen J; Amara K; Murray F; Szwajda A; Liu A; Douagi I; Malmstrom V; Frostegard J
Article: JOURNAL OF MOLECULAR BIOLOGY. 2012;417(4):279-293
Crystal Structure of Bifunctional Aldos-2-Ulose Dehydratase/Isomerase from Phanerochaete chrysosporium with the Reaction Intermediate Ascopyrone M
Claesson M; Lindqvist V; Madrid S; Sandalova T; Fiskesund R; Yu S; Schneider G
Article: RESULTS IN IMMUNOLOGY. 2012;2:13-18
IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL.
Fiskesund R; Su J; Bulatovic I; Vikström M; de Faire U; Frostegård J
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2011;29(6):942-950
Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis: a one-year study
Ajeganova S; Fiskesund R; de Faire U; Hafstrom I; Frostegard J
Article: STROKE. 2010;41(4):607-612
Low Levels of Antibodies Against Phosphorylcholine Predict Development of Stroke in a Population-Based Study From Northern Sweden
Fiskesund R; Stegmayr B; Hallmans G; Vikstrom M; Weinehall L; de Faire U; Frostegard J
Journal article: ATHEROSCLEROSIS PLUS. 2009;10(2):e1290
Abstract: P1235 LOW LEVELS OF NATURAL ANTIBODIES AGAINST PHOSPHORYLCHOLINE PREDICT DEVELOPMENT OF STROKE
Fiskesund R; Stegmayr B; Hallmans G; de Faire U; Frostegård J
Article: JOURNAL OF APPLIED MICROBIOLOGY. 2009;106(2):624-633
Inhibition spectrum studies of microthecin and other anhydrofructose derivatives using selected strains of Gram-positive and -negative bacteria, yeasts and moulds, and investigation of the cytotoxicity of microthecin to malignant blood cell lines
Fiskesund R; Thomas LV; Schobert M; Ernberg I; Lundt I; Yu S

Alla övriga publikationer

Preprint: SSRN ELECTRONIC JOURNAL. 2018
Cell Softness Prevents Cytolytic T Cell Killing of Tumor-Repopulating Cells
Liu Y; Zhang T; Zhou N; Fiskesund R; Liang X; Chen J; Lv J; Xie J; Ma J; Zhang H; Tang K; Mo S; Cheng F; Zhou Y; Fang Y; Zhang X; Wang N; Huang B
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):348
Fully human monoclonal antibodies to phosphorylcholine improves phagocytosis efficiency in human peripheral blood monocytes derived macrophages
Thiagarajan D; Frostegard A; Fiskesund R; Steen J; Malmstrom V; Frostegard J
Review: PLANTA MEDICA. 2010;76(15):1635-1641
1,5-Anhydro-D-Fructose and its Derivatives: Biosynthesis, Preparation and Potential Medical Applications
Fiskesund R; Abeyama K; Yoshinaga K; Abe J-I; Yuan Y; Yu S
Review: BIOCHIMICA ET BIOPHYSICA ACTA: INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND BIOPHYSICS. 2006;1760(9):1314-1322
The anhydrofructose pathway and its possible role in stress response and signaling
Yu S; Fiskesund R

Forskningsbidrag

Development and evaluation of neutrophil transfusion to treat antibiotic resistant infections in neutropenic patients
Swedish Research Council
1 January 2022 - 31 December 2024
Development and evaluation of neutrophil transfusion to treat antibiotic resistant infections in neutropenic patients
Swedish Research Council
1 December 2020 - 31 December 2021

Anställningar

Biträdande Lektor, Medicin, Huddinge, Karolinska Institutet, 2022-2028

Examina och utbildning

Medicine Doktorsexamen, Institutet för miljömedicin, Karolinska Institutet, 2014
Läkarexamen, Karolinska Institutet, 2009

Om mig

Forskningsbeskrivning

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI